A Phase 4 interventional study of Fentanyl and Methadone in Opioid Use Disorder, sponsored by Pouya Azar. Completed at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Pouya Azar · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Opioid-Related Disorders with a site in Canada — 11 open to participants now, 12 under way, 1 of them phase 3. Opioid-Related Disorders · Canada.
Among the 36 studies in Opioid-Related Disorders with a site in Canada, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 in phase 4, and was the 27th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →11 of the 36 studies in Opioid-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:
Pouya Azar · Sites in Canada
Ages 19+
Eli Lilly and Company · Sites in Canada, United States, Puerto Rico and 1 more country
Ages 18–75
University of British Columbia · Sites in Canada
Ages 19–75
University of British Columbia · Sites in Canada
BC Centre on Substance Use · Sites in Canada
Ages 25+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 6 · Phase 4 9
First in 2005; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 51 across the 32 interventional studies, 260 across the 4 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
Pouya Azar is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Pouya Azar has 3 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Opioid-Related Disorders with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03675386University Health Network, TorontoReducing Opioid Use for Chronic Pain Patients Following Surgery | 2026-12-31 |
| NCT07546396Pouya AzarMethadone Rapid Restart | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Opioid-Related Disorders with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test a treatment strategy for individuals with opioid use disorder (OUD) who use fentanyl. Participants will receive medically-administered doses of intravenous (IV) fentanyl at intervals until they are comfortable and do not have withdrawal symptoms. They then will be given opioid agonist therapy (OAT) once daily by mouth, which is the current standard treatment for OUD. In this trial, each participant's starting dose of OAT will be tailored to meet their opioid needs, based on the amount of IV fentanyl they received.
The main questions this trial aims to answer are:
This is an open-label, single arm, prospective clinical trial involving 50 individuals with opioid use disorder (OUD) who use illicit fentanyl and for whom opioid agonist therapy (OAT) with either methadone or slow-release oral morphine (SROM) is clinically indicated. Participants who provide informed consent and are found to be eligible will undergo a "symptom-inhibited" fentanyl induction procedure under close medical supervision in a community clinic. A study doctor or nurse will administer intravenous (IV) fentanyl at 5-minute intervals until the participant indicates comfort and their opioid withdrawal symptoms are minimized, or until their sedation level is 2 on the Pasero Opioid-induced Sedation Scale (POSS). Immediately before the first dose of fentanyl, after each dose during the induction procedure, and every 5 minutes for 15 minutes (or until stable) after the final fentanyl dose, study staff will monitor the participants' level of sedation (POSS), withdrawal symptoms (Clinical Opiate Withdrawal Scale, COWS), and vital signs (heart rate, respiratory rate, blood pressure, oxygen saturation).
Selection of the appropriate OAT agent for each participant will be done in advance by the clinical addictions management team. Participants with a QTc interval >500 msec on screening ECG will not be eligible to receive methadone, and will be offered SROM if clinically appropriate. Participants with known chronic kidney disease will have serum creatinine tested for calculation of estimated glomerular filtration rate (eGFR) if they are to receive SROM; if eGFR is between 15 and 60 mL/min, SROM doses will be adjusted according to current recommendations [Lexicomp 2021]; if eGFR\<15 mL/min, the participant will not be eligible to receive SROM.
The total cumulative dose of IV fentanyl administered during the induction phase (the loading dose) x 8 will be used as a proxy for the individual's 24-hour opioid tolerance, which in turn will be converted to oral morphine equivalents and used to calculate the appropriate starting dose of methadone or SROM, up to a maximum daily dose of 200 mg for methadone or 2000 mg for SROM. The first OAT dose will be administered under observation in the clinic, preferably on the same day and 15-30 minutes after the completion of the induction procedure. Participants will remain in the clinic under observation for 3 hours after the first dose of methadone or SROM. Vital signs, POSS, and COWS will be monitored before the first OAT dose, then hourly and prior to discharge. Study staff will assess the participants' satisfaction with the symptom-inhibited fentanyl induction process, using the single item Medication Satisfaction Questionnaire (MSQ) and 3-open ended questions. Participants will be discharged from the clinic when medically stable.
Participants will return to the study clinic once daily for 7 days for OAT dispensing and assessment of activity level in the previous 24 hours, vital signs, POSS, and COWS. An ECG will be performed on OAT Days 3 (+/- 2 days) and 7 (+/- 2 days) for participants receiving methadone. Methadone will be preferentially be maintained at the same dose for the first 7 days; however, methadone dose may be adjusted (up to a maximum daily dose of 200 mg) if felt to be safe and clinically indicated. SROM doses may be increased by 100 mg every 24-48 hours (consistent with current clinical guidelines from the British Columbia Centre on Substance Use) up to a maximum daily dose of 2000 mg if clinically indicated (presence of cravings or withdrawal symptoms, and absence of SROM-related adverse events and opioid toxicity).
After Day 7, OAT will be dispensed through a community pharmacy according to standard procedure. Participants will return to the study clinic for the following assessments at 7 days (up to +2 days) , 1 month (+/- 2 weeks), 3 months (+/- 1 month), 6 months (+/- 2 months), and 12 months (+/- 3 months) post-induction:
At the same time points, additional information will be obtained from the clinic's electronic medical record (EMR) database:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symptom-inhibited IV fentanyl induction followed by opioid agonist therapy (OAT) with either oral methadone or slow-release oral morphine (SROM)
Drug: Fentanyl · Drug: Methadone · Drug: Slow-release oral morphine
Symptom-inhibited IV fentanyl induction
Also known as: Fentanyl citrate, Fentanyl injection
Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
Also known as: Methadone hydrochloride, Methadone oral product
Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
Also known as: SROM, Kadian
Number of clinically significant study drug-related adverse events requiring intervention
Total number of clinically significant study drug-related adverse events (e.g. sedation, respiratory depression, hypoxia, QT prolongation) requiring intervention, occurring during the first week
Time frame: Count starting from the beginning of the IV fentanyl induction procedure up to the end of Day 7 on OAT
Starting doses of oral OAT
Starting doses of methadone or slow-release oral morphine (SROM)
Time frame: Immediately after IV fentanyl induction
OAT retention
Proportion of participants who are retained on OAT
Time frame: Days 1-7 and 1, 3, 6, and 12 months after IV fentanyl induction
Participant satisfaction with fentanyl induction
Qualitative interview and single-item Medication Satisfaction Questionnaire (MSQ)
Time frame: First 1 to 3 hours after IV fentanyl induction
Participant satisfaction with current OAT
Single-item MSQ
Time frame: Before IV fentanyl induction, and at Day 7 and 1, 3, 6, and 12 months after IV fentanyl induction
Withdrawal symptoms
Clinical Opiate Withdrawal Scale (COWS) score
Time frame: Before, during, and during 1-3 hours after IV fentanyl induction; daily during first week on OAT; and at 1, 3, 6, and 12 months
Overdose events
Opioid overdose events requiring Intervention (acute care or hospitalization)
Time frame: Day 7 and 1, 3, 6, and 12 months
Hospitalizations
Inpatient hospital admissions for any cause
Time frame: Day 7 and 1, 3, 6, and 12 months
Death
Death
Time frame: Day 7 and 1, 3, 6, and 12 months
Ran from Jan 2024 to primary completion in Dec 2025, 23 months.
Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's 23 months is below that.
Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fentanyl